Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Classement en actions #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Prix de l'action
$150.78
Dernière synchronisation: 2026-09-18
Capitalisation boursière
$187.20B
Changement (1 jour)
-0.08%
Changement (1 an)
32.15%
Pays
US
Échange Gilead Sciences, Inc. (GILD)

Catégorie

Marge opérationnelle de Gilead Sciences, Inc. (GILD)
Marge opérationnelle au September 2026 TTM : -4.90%
Selon les derniers rapports financiers et le cours de l'action de Gilead Sciences, Inc., la marge opérationnelle actuelle (TTM) est de -4.90%. À la fin de 2024, elle était de 5.78%.
Historique de la marge opérationnelle pour Gilead Sciences, Inc. de 2000 à 2026
Marge opérationnelle à la fin de chaque année
Année Marge opérationnelle Changez
2026 (TTM) -4.90% -114.39%
2025 34.04% 488.93%
2024 5.78% -79.39%
2023 28.05% 4.39%
2022 26.87% -26.02%
2021 36.32% 120.25%
2020 16.49% -13.66%
2019 19.10% -48.46%
2018 37.06% -31.50%
2017 54.10% -6.76%
2016 58.02% -14.68%
2015 68.00% 10.88%
2014 61.33% 51.84%
2013 40.39% -2.27%
2012 41.33% -8.56%
2011 45.20% -9.31%
2010 49.84% -0.99%
2009 50.34% 0.28%
2008 50.20% -1.90%
2007 51.17% -304.11%
2006 -25.07% -145.85%
2005 54.68% 15.46%
2004 47.36% -359.08%
2003 -18.28% -205.36%
2002 17.35% -133.60%
2001 -51.63% 93.01%
2000 -26.75% 0.00%
Marge opérationnelle pour des entreprises similaires ou concurrentes
Entreprise Marge opérationnelle Différence de Marge Opérationnelle Pays
43.92% -108.96%
US
26.81% -105.47%
US
29.32% -105.98%
US
26.59% -105.43%
CH
16.65% -103.40%
US
Qu'est-ce que la Marge opérationnelle d'une entreprise ?
La Marge opérationnelle est un indicateur clé pour évaluer la rentabilité d'une entreprise. Une marge d'exploitation plus élevée est généralement préférable car elle montre qu'une entreprise peut vendre ses produits ou services bien au-dessus de leurs coûts de production. Elle se calcule en divisant les bénéfices par le chiffre d'affaires.